Currently, two licensed anti-AD drugs (galantamine and rivastigmine) are based on plant-derived natural products, in addition to the fact that natural products targeting tau aggregation in AD pathogenesis are also reported [38]. This evidence concerns the gene MAPT and Alzheimer disease.